FeesSafety
Pluang+

Generate Biomedicines reports Q3 2026 results, advances asthma drug GB-0895 and new collaborations in AI and oncology.

Company Fundamentals
12 Nov 2026, 14:20 WIB
GlobeNewsWire
View Source
Bullish
Generate Biomedicines reports Q3 2026 results, advances asthma drug GB-0895 and new collaborations in AI and oncology.

Generate Biomedicines announced its Q3 2026 financial results, highlighting progress with GB-0895, an AI-engineered drug for severe asthma and COPD, currently in Phase 3 trials. The company also entered a $30 million collaboration with Zealand Pharma to develop protein therapeutics for metabolic diseases and partnered with Anthropic on AI-driven CAR T-cell research. Oncology programs advanced with new patient dosing in trials for urothelial and ovarian cancers. With $404.2 million in cash and securities, Generate expects funding through mid-2028 but anticipates needing more capital for long-term operations.

Generate Biomedicines reports Q3 2026 results and business updates. For readers following the health sector, here is Pluang's market snapshot as of Nov 12, 2026 19:11 WIB: Among 150 priced US health stocks, 91 rose and 53 fell. Notable movers include NUWE at USD 5.66 (+2.35%), AHCO at USD 7.62 (-2.31%), and TAK at USD 21.30 (+2.21%) with 100% buy activity on TAK and 100% sell activity on NUWE and AHCO.

More News

Tilray's 10 Barrel, Widmer Brothers, and Hop Valley named official craft beer partners of Portland Trail Blazers.

Tilray's 10 Barrel, Widmer Brothers, and Hop Valley named official craft beer partners of Portland Trail Blazers.

Tilray Brands announced that its subsidiaries 10 Barrel Brewing, Widmer Brothers Brewing, and Hop Valley Brewing are now the official craft beer partners of the Portland Trail Blazers. This partnership expands the availability of Oregon craft beers a...

Market News
Bullish
36 minutes ago
Titan Mining's nine-month Adjusted EBITDA jumps 146% to $19.8M, advancing U.S. critical minerals projects.

Titan Mining's nine-month Adjusted EBITDA jumps 146% to $19.8M, advancing U.S. critical minerals projects.

Titan Mining reported a 146% increase in nine-month Adjusted EBITDA to $19.8 million, driven by a 38% rise in revenue to $67.9 million. Despite some production delays, zinc output is expected to improve in Q4 2026. The company is progressing its U.S....

Company Fundamentals
Bullish
1 hour ago
Nexpu completes delivery of 10,000 resale robots worth $4.8M under existing contract

Nexpu completes delivery of 10,000 resale robots worth $4.8M under existing contract

Nexpu Ltd.'s subsidiary, Top Kingwin Hi Tech Inc., has finished delivering all 10,000 TK-D2C robots to Walkers Times International under a $4.8 million resale contract signed in 2025. The deliveries were completed in batches, with the final 5,000 uni...

Market News
Bullish
1 hour ago
Katapult Holdings reports Q3 2026 results with $753.9M revenue, $110.4M adjusted EBITDA, and $30M cost synergies from merger.

Katapult Holdings reports Q3 2026 results with $753.9M revenue, $110.4M adjusted EBITDA, and $30M cost synergies from merger.

Katapult Holdings announced its third quarter 2026 financial results, reporting total revenues of $753.9 million and an adjusted EBITDA of $110.4 million, reflecting a 23% increase year-over-year on a combined basis. The company completed a merger wi...

Company Fundamentals
Neutral
1 hour ago
Three-quarters of U.S. workers plan to freelance within 3 years, valuing independence over salary.

Three-quarters of U.S. workers plan to freelance within 3 years, valuing independence over salary.

A new report from Fiverr reveals that 81% of full-time U.S. employees want to become their own boss, with 42% prioritizing independence over higher pay. This trend, dubbed "The Great Flexit," shows workers quietly preparing to freelance by building A...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App